"No, this AACR poster is for the prostate cancer program, not the pending breast cancer program."

The AACR poster refers to this ongoing Phase 1b/2a mCRPC trial for ZEN-3694 in combo with enzalutamide in mCRPC. Completion date of this trial is currently listed as June 2019. At the very least, this poster is presenting trial design and background for the combo trial.....potentially some of the single agent ZEN-3694 Phase 1 data too. However, since this is an open label trial, they may be presenting the current Phase 1b/2a trial data for the combo therapy similar to what gets shown in the Zenith Corporate updates.

https://clinicaltrials.gov/ct2/show/NCT02711956